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Abstract
Background: There is increasing recognition of the delicate balance between the modest benefits of palliative
chemotherapy and the burden of treatment. Decision aids (DAs) can potentially help patients with advanced
cancer with these difficult treatment decisions, but providing detailed information could have an adverse impact on
patients' well-being. The objective of this randomised phase II study was to evaluate the safety and efficacy of DAs
for patients with advanced cancer considering second-line chemotherapy.
Methods: Patients with advanced breast or colorectal cancer considering second-line treatment were randomly
assigned to usual care (control group) or usual care plus a DA (intervention group) in a 1:2 ratio. A nurse offered a DA
with information on adverse events, tumour response and survival. Outcome measures included patient-reported well-
being (primary outcome: anxiety) and quality of the decision-making process and the resulting choice.
Results: Of 128 patients randomised, 45 were assigned to the control group and 83 to the intervention group. Median
age was 62 years (range 32-81), 63% were female, and 73% had colorectal cancer. The large majority of patients
preferred treatment with chemotherapy (87%) and subsequently commenced treatment with chemotherapy (86%). No
adverse impact on patients' well-being was found and nurses reported that consultations in which the DAs were
offered went well. Being offered the DA was associated with stronger treatment preferences (3.0 vs. 2.5; p=0.030) and
increased subjective knowledge (6.7 vs. 6.3; p=0.022). Objective knowledge, risk perception and perceived involvement
were comparable between the groups.
Conclusions: DAs containing detailed risk information on second-line palliative treatment could be delivered to
patients with advanced cancer without having an adverse impact on patient well-being. Surprisingly, the DAs only
marginally improved the quality of the decision-making process. The effectiveness of DAs for palliative treatment
decisions needs further exploration.
Trial registration: Netherlands Trial Registry (NTR): NTR1113 (registered on 2 November 2007)
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Background
While patients with advanced cancer beyond cure are
commonly offered palliative chemotherapy, there is in-
creasing recognition of the delicate balance between the
modest benefits of palliative chemotherapy and the bur-
den of treatment [1–6]. Survival gains are usually in the
range of weeks or months [7, 8], and while palliative
chemotherapy can relieve symptoms and enhance quality
of life [9], receiving palliative chemotherapy near the end
of life has also been associated with receiving more ag-
gressive medical care and worse quality of death [3, 10].
Furthermore, after failure of a first line of chemotherapy
given with palliative intent, benefits of further lines of
chemotherapy tend to be more limited. Therefore, starting
first-line and particularly further-line palliative chemother-
apy in addition to best supportive care should be carefully
considered and any treatment implemented should be in
harmony with the patient's preferences [5, 11, 12].
Alarmingly, in recent studies from the US, 52% and 69-
81% of patients receiving palliative chemotherapy seemed
to be under the false impression that this treatment may
well cure their cancer [13, 14]. This inaccurate under-
standing may be related to incomplete communication by
the oncologists, as well as patients' inability to accept the
incurable nature of their disease [14]. Indeed, there are in-
dications that clinicians and patients purposefully use a
strategy of 'collusion' to communicate about the future,
including avoiding or delaying the discussion of estimated
life expectancy, in an effort to preserve patients' hope
[15–19].
Decision aids (DAs) with information about risks and
benefits of treatment options can potentially support pa-
tients in these difficult treatment choices. There is solid
evidence from diverse healthcare settings that DAs can
help patients to increase their knowledge and establish
realistic expectations, and become more involved in
making treatment decisions [20]. While designed to fa-
cilitate patient centered care, offering DAs with detailed
information about estimated life expectancy for treat-
ment with and without palliative chemotherapy may be
at odds with clinicians' and patients' preferred strategy
of 'collusion'. Studies have indicated that patients with a
worse prognosis usually preferred less information and a
less active role in decision-making [21, 22], while having
prognostic discussions and encouraging patients to be-
come more involved have been shown to be associated
with increased anxiety among patients receiving or eli-
gible for palliative chemotherapy [13, 23, 24]. Increased
anxiety was also reported by patients who initially wel-
comed detailed prognostic information [13].
Several DAs have been developed to support decisions
about palliative chemotherapy, most of them pertaining
to decisions about first-line treatment [25–33]. Encour-
agingly, this series of mostly pilot studies have generally
demonstrated good acceptability, although some patients
thought the information was sad or too frank and caused
distress or did not promote hope [25, 27, 28]. Beneficial
effects included improved knowledge [28, 29, 31, 33] and
stronger treatment preferences [30]. In addition, a number
of DAs have been developed for advance care planning
(i.e. future decisions) in patients with (advanced) cancer
[34–37]. Acceptability of these DAs was generally high
[35–37] and users demonstrated higher levels of know-
ledge [37] while their levels of hope and anxiety remained
unchanged [35].
The aim of this study is to evaluate the feasibility of of-
fering DAs containing detailed information about esti-
mated life expectancy to patients with advanced breast or
colorectal cancer considering second-line palliative
chemotherapy, using a randomised multicentre design.
Our primary aim was to evaluate any harmful effects of
the DAs as compared with usual care, regarding patients’
well-being and specifically anxiety. Given patients' poten-
tial vulnerability, information was not routinely offered
but patients were asked whether they wished to receive
detailed information from the DA. In addition, we ex-
plored whether the previously reported beneficial effects
of DAs also apply to palliative treatment decisions.
Methods
Study design
This randomised phase II study evaluating the fea-
sibility of decision aids for second-line palliative
chemotherapy was conducted in 17 hospitals in the
Netherlands. The study was prospectively registered
(Netherlands Trial Registry; NTR1113 http://www.trial
register.nl/trialreg/admin/rctview.asp?TC=1113), and a
detailed account of the study design is available in the
study protocol [38] (see Additional file 1). In summary,
the decision aid offered information for patients con-
sidering second-line palliative chemotherapy for ad-
vanced breast or colorectal cancer. To identify patients
who would be offered second-line palliative chemother-
apy, we approached patients receiving first-line pallia-
tive chemotherapy for advanced incurable disease.
Patients were excluded in case of a labile personality
structure (as assessed by the medical oncologist), a
Karnofsky performance score lower than 60, and insuf-
ficient Dutch language proficiency.
Recruitment
Initial screening of potentially eligible patients against
the selection criteria was performed by a medical on-
cologist or nurse. Eligible patients were approached
by the health professional to ask permission for a re-
searcher to contact them about a study testing a new
way of providing information to patients. Importantly,
health professionals did not mention that explicit
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information on expected survival would be offered to
patients, in an effort to prevent selection of patients
not wishing to receive such information.
Procedure
When a patient included in the study experienced dis-
ease progression and was offered second-line chemo-
therapy, randomisation was performed. A nurse would
open a sealed envelope to find out whether the patient
would either: (1) be informed by the oncologist in the
usual way (control group); or (2) be informed by the
oncologist in the usual way followed by a consultation
with a nurse offering a DA (intervention group). Un-
equal randomisation (using a 1:2 ratio) was used be-
cause the sample size of the control group was based
on the current evaluation of the DAs, while the sample
size of the intervention group was based on more
detailed analyses of patients' desire for information
[38, 39]. Randomisation lists were computer generated
per hospital and tumour type, using a block size of 3.
Patients in the intervention group were offered an ap-
pointment with a nurse to receive the DA, typically
within a week after the oncologist imparted the news
of disease progression and discussed treatment op-
tions (depending on local workflow and patient
preferences).
The DAs
The DA booklets were designed based on our previous ex-
perience with DAs for prostate cancer treatment [40, 41],
and we followed guidance from the International Patient
Decision Aids Standards where possible [42]. The booklets
started with an introduction describing both treatment
options and showing an example of numerical information
provided. In the next section, numerical information was
provided on: (1) the incidence of adverse events; (2) the
chances of achieving a tumour response; and (3) expected
median survival. This information was derived from sys-
tematic reviews of the literature for the two tumour types
[7, 8], and tailored to the particular type of chemotherapy
offered to the patient (for a total of eleven types of chemo-
therapy). Figure 1 shows an example of the information
shown in a DA for second-line irinotecan; a full copy of a
DA is available in Additional file 2.
Measures
Oncologists completed an inclusion form (see Additional
file 3) and nurses completed a brief questionnaire about the
interview with the DA (see Additional file 4). Patients were
asked to complete a first questionnaire at inclusion (T1)
and patients in both groups were asked to complete two
follow-up questionnaires one week (T2) and eight weeks
(T3) after receiving treatment-related information. Patient
questionnaires are available in Additional files 5, 6 and 7.
Sociodemographic variables and medical history
Patient’s gender and tumour type were extracted from
the inclusion form. The baseline questionnaire contained
questions on age, level of education, marital and working
status, and having children or grandchildren.
Intervention interview
Nurses were given a paper-and-pencil questionnaire di-
vided into two sections (see Additional file 4). The first
section was completed during the interview with the pa-
tient and started with a question about treatment prefer-
ence and strength of this preference. After that, the
nurse administered the DA.
The nurse first introduced the DA and the two options
for second-line treatment (best supportive care with or
without second-line palliative chemotherapy) and
showed an example of risk information. The nurse then
proceeded to offer information for the first item, adverse
events. First the patient was given a brief explanation of
the type of information to be expected (e.g. implications
of a severe adverse event) and then the patient could in-
dicate whether he or she wished to receive the informa-
tion. The information was provided accordingly. A
booklet with information tailored to the patient’s desire
was available to take home.
To conclude the first section of the interview, the
nurse asked the patient once more about treatment pref-
erence and strength of this preference. Nurses were
instructed to complete the second section after the con-
sultation with the patient. This section included a ques-
tion about how the interview went, and the nurse was
asked to record which chemotherapeutic drug was dis-
cussed with the patient.
Outcome measures
Since this is one of the first randomised studies evaluating
the safety and efficacy of a DA in a population of advanced
cancer patients deciding about palliative chemotherapy,
we decided to explore a broad range of outcomes to assess
safety in this potentially vulnerable population, and assess
whether the previously found beneficial effects can be rep-
licated in this population. Therefore the selection of out-
come measures was largely based on outcomes used in
previous research [43].
Given the concerns about anxiety in this potentially vul-
nerable patient population, the primary outcome of this
study was selected to be anxiety. At the time the sample
size calculation was conducted, no information was avail-
able about the minimal clinically important difference for
the HADS anxiety scale. We had to resort to an educated
guess and decided to use a difference of 2.2, equivalent to a
difference of >10% on a scale of 0-21. Recent studies,
albeit in populations of patients with COPD and survi-
vors of acute respiratory failure [44–46], seem to
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indicate that the estimate of 2.2 was not unreasonable.
The primary outcome measure anxiety was defined a
priori, and all main and additional outcome measures
have been described beforehand in the publicly available
study protocol [38]. The outcomes of our exploratory ana-
lysis of additional outcome measures were interpreted
with appropriate caution, and any statistically significant
findings will need to be confirmed by future studies [47].
An overview of outcome measures and operationalisation
is shown in Table 1.
Main outcome measures The primary outcome meas-
ure of this study was anxiety [48]. Four other measures
of patient well-being were used, including general health,
health-related quality of life (HRQoL) [49], depression
[48], and cancer worries [50].
Additional outcome measures
Coping
Patients were asked questions on their mental adjust-
ment to cancer, including their style of coping including
helplessness/hopelessness, fighting spirit, and avoidance
[51]. In addition, patients were asked questions on per-
ceived participation and perceived involvement including
the perception of being offered a choice and the percep-
tion that their opinion mattered [52, 53].
Fig. 1 Example of a summary page of a DA for colorectal cancer
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Table 1 Overview of outcome measures
Timing of measurements1
Measures Operationalisation Baseline
T1
1 week
follow-up
T2
8 weeks
follow-up
T3
Main outcome measures
Well-being
Anxiety2 Hospital Anxiety and Depression Scale x x x
Depression Hospital Anxiety and Depression Scale x x x
General health 0-10 (worst-best imaginable) x x x
Cancer Worries Adapted Lerman’s Cancer Worry Scale x x x
Health-related quality of life EORTC QLQ-C15-PAL x x x
Additional outcome measures
Coping
Helplessness/hopelessness Mental Adjustment to Cancer Scale x x x
Fighting spirit Mental Adjustment to Cancer Scale x x x
Avoidance Mental Adjustment to Cancer Scale x x x
Perceived participation Problem-Solving Decision Making Scale x x
Perceived involvement yes/no x x
Information-related measures
Amount of information 1-7 (I received way too little-way too much information) x x x
Undesired information yes/no x
Satisfaction with quality of information 1-6 (not satisfied-very much satisfied) x x
Balanced presentation of information 1-5 (clearly in favour of chemotherapy plus BSC -
clearly in favour of BSC alone)
x
Evaluation of information 1-5 (no negative experience-very negative experience) x
Knowledge
Subjective knowledge 1-10 (extremely poor-excellent) x x
Objective knowledge five statements to be judged as right or wrong x
Subjective risk perception 1-5 (very high-very low)3 x
1-7 (much higher-much lower)4 x
Objective risk perception 0-100%5 x
Decision-related measures
Decision satisfaction-uncertainty Decision Evaluation Scales x x
Decision control Decision Evaluation Scales x x
Weighing pros and cons Decision Evaluation Scales x x
Treatment choice chemotherapy + BSC /BSC alone/don’t know x x
Strength of treatment preference 1-5 (not strong-very strong)6 x
Treatment attitudes
Valuations 1-10 (extremely poor-excellent) x x
Treatment satisfaction 1-6 (dissatisfied-very satisfied) x
Abbreviation: BSC best supportive care
1Baseline: at inclusion; follow-up: 1 and 8 weeks after receiving the treatment-related information
2Anxiety is the primary outcome measure
3Question 1: 'the chance of experiencing an adverse event'
4Question 2: 'the chance of experiencing a beneficial effect on the tumour when having treatment with chemotherapy and BSC, as compared with
BSC alone' and question 3 'the chance of experiencing pain when having treatment with chemotherapy and BSC, as compared with BSC alone'
5The absolute deviation between patient's objective risk perception and the actual risk (as identified in the literature reviews [7, 8] and presented in
the DAs) was calculated.
6For patients whose treatment choice was ‘undecided’, the strength of the treatment preference was scored as zero
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Information-related measures
Questions were asked about the amount of treatment-
related information received and about receiving any un-
desired information. Furthermore, patients were asked to
rate the quality of information, whether treatment options
were presented in a balanced way, and whether they had
any negative experiences with the information received.
Knowledge
Patients rated their knowledge about cancer and its
treatment, and were presented with five statements,
judged to be right or wrong, to assess objective know-
ledge. For subjective risk perception, patients were asked
to rate the following chances: (1) the chance of experien-
cing an adverse event, (2) the chance of experiencing a
beneficial effect on the tumour when having treatment
with chemotherapy and BSC, as compared with BSC
alone, and (3) the chance of suffering from pain when
opting for chemotherapy, as compared with BSC alone.
Objective risk perception was assessed by asking for the
chances of: (1) experiencing severe diarrhoea and (2)
achieving partial or complete tumour response. The for-
mat of these questions was mostly based on knowledge
questions in other studies [20] and our own previous
work [40, 41] and the content was informed by key in-
formation provided in the decision aid, e.g. adverse
events and tumour response.
Decision-related measures
The decision was evaluated with questions about pa-
tients' satisfaction and uncertainty around the decision,
patients' sense of control in the treatment decision, and
deliberation of pros and cons of treatment options [54].
Furthermore, patients were asked about their preferred
treatment, and, if applicable, the strength of that prefer-
ence (T2), and about the treatment they actually re-
ceived (T3).
Treatment attitudes
Patients were asked about treatment attitudes because
these are considered to be one of the main determinants
of (health) behaviour, according to theories for behaviour
and behaviour change [55]. Patients were asked to value
each of the two treatment options on a scale of 1-10
(T2 and T3), and rate their satisfaction with (1) the
implemented treatment; (2) the physical consequences
of treatment and (3) the emotional consequences of
treatment (1 'dissatisfied' - 6 'very satisfied') at T3.
Statistical Analysis
To assess the risk of attrition bias, characteristics of
randomised patients were compared with inadvertently
non-randomised patients, using independent samples
t-tests or Chi-Square tests, as applicable. The safety and
efficacy of the DAs were assessed by comparing patients
in the intervention and control groups, on an intention-
to-treat basis. Nominal variables were analysed using the
Chi-Square test of independence. Interval variables that
were available for a single follow-up measurement were
analysed using an independent samples t-test, Chi-Square
test of independence or Fisher Exact Test or, if a base-
line measurement was available, analysis of covariance
(ANCOVA). Interval variables that were available for both
follow-up measurements were analysed using linear mixed
models. In these models, dependent variables were the two
follow-up measurements (T2 and T3), and covariates were
the variables ‘group’, ‘time’, an interaction term between
'group' and 'time' and if available, 'baseline measurement'.
The covariates 'group*time', 'time', and 'baseline measure-
ment' were stepwise removed from the model based on
statistical significance. To accommodate the repeated
measures we used a heterogeneous compound symmetry
error structure.
Results
Patients
Screening of potentially eligible patients took place be-
tween February 2008 and April 2012. As shown in Fig. 2,
out of 441 patients screened, 34 patients (8%) were not
approached by the oncologist and therefore the selection
criteria could not be verified. Another 86 patients (20%)
did not fulfil the selection criteria. Out of the remaining
321 patients, 263 (82%) agreed to participate and gave
informed consent.
Over time, 171 included patients (65%) faced the deci-
sion on second-line treatment and were eligible for
randomisation. However, 43 of them (16%) were not
randomised and dropped out of the study. To assess se-
lective attrition, we compared characteristics between
these 43 patients and the 128 patients who were rando-
mised and found that patients were similar with regard
to gender, age, education, tumour type, information pref-
erence and general health.
Out of 128 patients randomised, 45 were randomly
assigned to the control group and 83 were assigned to re-
ceiving the DA in addition to usual care. Characteristics of
randomised patients are shown in Table 2. The two groups
were similar with regard to baseline characteristics.
Intervention interview
In the intervention group, 77 patients (93%) completed
the intervention interview with a nurse offering the DA.
A total of 20 nurses (between 1 and 3 per hospital) were
involved in conducting the intervention interviews
(median number of interviews conducted: 2; range 1-22).
The majority opted to be shown the information in the
DA with regard to (1) adverse events (96%); (2) tumour
response (91%); and (3) survival (74%). Nurses felt that
90% of the interviews went (very) well.
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Outcomes
Table 3 provides a comparison of outcomes for the main
outcome measures and additional outcomes measured at
both follow-up moments (T2 and T3), analysed using
linear mixed models. The variable ‘group’ was retained
in all models to assess the effect of the DA. Table 4
provides a comparison of additional outcomes between
groups at a single follow-up moment (T2 or T3).
Main outcome measures
Receiving the DA was not related to any of the measures
for well-being, including the primary outcome anxiety
(Table 3). In both groups, average anxiety scores were
approximately 6 on a 0-21 scale, and the difference be-
tween the groups was -0.1 (95% CI -1.1;0.9). When using
a threshold of 8 or 11 [56], heightened levels of anxiety
and/or depression were detected in 6-33% of all patients
at T1, 10-38% of patients at T2 and 10-33% of patients
at T3, which is similar to other populations of patients
with advanced cancer.
Additional outcome measures
Coping Patients in the intervention and control groups
reported equal levels of helplessness/hopelessness, fighting
spirit, avoidance, and perceived participation (Table 3) and
perceived involvement (Table 4).
Table 2 Patient characteristics
Intervention
group
(n=83)
Control
group
(n=45)
Male gender, n (%) 31 (37%) 16 (36%)
Age, mean (SD) 61 (9.1) 62.5 (9.5)
Living with partner, n (%) 64 (77%) 37 (82%)
Employed, n (%) 25 (30%) 13 (29%)
Having children, n (%) 74 (89%) 38 (84%)
Having grandchildren, n (%) 44 (53%) 26 (58%)
College education or more, n (%) 24 (29%) 7 (16%)
Tumour characteristics
Colorectal cancer, n (%) 61 (73%) 32 (71%)
Breast cancer, n (%) 22 (27%) 13 (29%)
Fig. 2 Flow diagram
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Table 3 Comparison of outcomes over multiple time points (T2 and T3)
Linear mixed models
Measure (answer scale)1 Intervention group2
Mean (SD)
Control group2
Mean (SD)
Covariates
in model
Difference between intervention and
control group averaged
over T2 and T3,
adjusted for T13
(95% CI)
Two- sided
p value
Main outcome measures
Well-being
Anxiety4 (0-21 ) T1 5.7 (4.0) 5.6 (4.0) Group -0.1 (-1.1;0.9) 0.808
T2 6.6 (4.5) 6.1 (4.5) Baseline
T3 5.5 (4.1) 5.9 (4.6) Time
Depression (0-21) T1 5.1 (3.6) 4.1 (3.0) Group -0.7 (-1.7;0.3) 0.142
T2 5.6 (4.2) 5.6 (4.2) Baseline
T3 5.3 (3.6) 5.2 (3.5)
General health (0-10) T1 6.5 (1.6) 7.1 (1.7) Group -0.2 (-0.8;0.5) 0.615
T2 5.7 (1.8) 6.1 (1.9) Baseline
T3 5.8 (2.0) 5.9 (1.7)
Cancer worries (1-4) T1 2.1 (0.6) 2.0 (0.6) Group -0.1 (-0.3;0.1) 0.192
T2 2.1 (0.5) 2.1 (0.6) Baseline
T3 2.1 (0.6) 2.2 (0.7)
HRQoL: physical functioning (0-100) T1 75.2 (22.3) 79.2 (18.1) Group -2.2 (-9.2;4.8) 0.536
T2 68.2 (22.5) 72.3 (21.0) Baseline
T3 67.9 (25.0) 71.1 (22.1)
HRQoL: emotional functioning (0-100) T1 81.0 (22.0) 80.5 (20.2) Group 3.5 (-3.4;10.5) 0.318
T2 74.3 (22.0) 73.6 (27.1) Baseline
T3 79.7 (20.2) 75.5 (25.2)
Additional outcome measures
Coping
Helplessness/Hopelessness (1-4) T1 1.8 (0.6) 1.7 (0.5) Group 0.0 (-0.1;0.2) 0.759
T2 1.8 (0.6) 1.8 (0.5) Baseline
T3 1.9 (0.6) 1.8 (0.5)
Fighting Spirit (1-4) T1 2.9 (0.6) 3.2 (0.6) Group -0.0 (-0.2;0.1) 0.568
T2 2.7 (0.6) 3.0 (0.6) Baseline
T3 2.8 (0.7) 2.8 (0.7)
Avoidance (1-4) T1 2.5 (0.7) 2.6 (0.8) Group 0.1 (-0.0;0.3) 0.094
T2 2.5 (0.7) 2.6 (0.7) Baseline
T3 2.5 (0.7) 2.3 (0.7)
Perceived participation (1-5) T2 3.1 (1.0) 2.8 (0.9) Group 0.2 (-0.2;0.5) 0.395
T3 2.9 (1.0) 2.9 (0.8)
Information-related measures
Amount of information received (1-7) T1 3.8 (0.6) 3.9 (0.3) Group -0.1 (-0.3;0.0) 0.157
T2 3.8 (0.7) 4.0 (0.4) Baseline
T3 3.8 (0.5) 3.9 (0.3)
Satisfaction with quality of information (1-6)
Severe adverse events T2 4.8 (0.9) 4.8 (1.0) Group 0.0 (-0.3;0.4) 0.802
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Information-related measures No differences were
found between the groups over time for the amount of in-
formation and satisfaction with the quality of information
(Table 3). Patients in both groups responded similarly to
questions about undesired information, balanced presen-
tation, and evaluation of the information (Table 4).
Knowledge Patients in the intervention group felt sig-
nificantly more knowledgeable compared with patients
in the control group (6.7 vs. 6.3; p=0.022). Objective
knowledge and subjective and objective risk perceptions
were similar between the groups (Table 4).
Decision-related measures At the first follow-up (T2)
the large majority of patients reported having a treat-
ment preference (95%); most of them favoured chemo-
therapy (87%). The two groups responded similarly to
questions about decision satisfaction and uncertainty,
decision control, and weighing of pros and cons (Table 3).
Patients in the intervention group reported stronger treat-
ment preferences (3.0 vs. 2.5; p=0.030). At T3, there were
no differences in treatment received between the groups
(Table 4).
Treatment attitudes Valuations of both treatment op-
tions were comparable between the groups (Table 3). In
both groups, treatment with chemotherapy was on aver-
age valued with a 7.4 while treatment with BSC alone
was valued with a 4.0 (on a scale of 1-10), resulting in a
mean difference of 3.4 (95% CI 2.8-4.1; p=0.000). As
shown in Table 4, patients in both groups felt equally
satisfied with their treatment and the consequences of
treatment (both physical and emotional).
Discussion
This study was designed to address concerns about of-
fering detailed treatment-related information to a poten-
tially vulnerable group of patients with advanced cancer
[13, 18, 19, 23]. In line with previous research in a wide
variety of patient populations [20] and patients with ad-
vanced cancer in an earlier stage of the treatment trajec-
tory [25, 33, 57], this study has not revealed an adverse
impact of decision aids in this patient population. The
large majority of patients opted to be shown all of the
available detailed information in the decision aid and
nurses reported that nearly all consultations went well.
Follow-up at 1 and 8 weeks did not reveal any harmful
effects on anxiety or other measures of well-being,
Table 3 Comparison of outcomes over multiple time points (T2 and T3) (Continued)
T3 4.5 (1.2) 4.4 (1.1) Time
Tumour response T2 4.5 (1.0) 4.4 (1.2) Group 0.1 (-0.2;0.5) 0.536
T3 4.3 (1.1) 4.2 (1.1)
Survival T2 4.0 (1.3) 4.0 (1.3) Group 0.1 (-0.3;0.6) 0.540
T3 4.0 (1.2) 3.6 (1.4)
Knowledge
Subjective knowledge5 T1 6.5 (1.2) 6.6 (1.0) Group 0.5 (0.1; 0.9) 0.022
T2 6.7 (1.2) 6.3 (1.3) Baseline
Decision-related measures
Decision satisfaction-uncertainty (1-5 ) T2 4.1 (0.6) 4.0 (0.7) Group 0.1 (-0.1;0.3) 0.155
T3 4.1 (0.6) 3.9 (0.4)
Decision control (1-5) T2 4.2 (0.7) 4.3 (0.6) Group -0.1 (-0.3;0.2) 0.617
T3 4.3 (0.6) 4.3 (0.6)
Weighing pros and cons (1-5) T2 4.2 (0.8) 3.9 (1.0) Group 0.2 (-0.1;0.5) 0.118
T3 4.0 (1.1) 3.8 (0.8)
Treatment attitudes toward both options
Valuations: chemotherapy + BSC (1-10) T2 7.5 (1.7) 7.2 (1.6) Group 0.1 (-0.5;0.7) 0.677
T3 7.1 (1.8) 7.3 (1.7)
Valuations: BSC alone (1-10) T2 3.7 (2.1) 4.3 (2.1) Group -0.4 (-1.2;0.3) 0.246
T3 4.1 (2.3) 4.6 (2.4)
Abbreviations: SD standard deviation, CI confidence interval, BSC best supportive care
1More information on the scales can be found in Table 1
2Intervention group: T1 n=82, T2 n=68, T3 n=58 Control group: T1 n=44, T2 n=40, T3 n=33
3Positive numbers represent higher scores in the intervention group
4Anxiety is the primary outcome measure
5Analysed using analysis of covariance (ANCOVA); difference between intervention and control group at T2, adjusted for T1
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including cancer worries, nor was receiving the decision
aid associated with having received undesired informa-
tion, reporting a more negative experience (e.g. receiving
threatening or frightening information), or increased
feelings of hopelessness.
With regard to efficacy, patients who were offered a
DA were found to have better subjective knowledge and
stronger treatment preferences. These are important
benefits. However, previous studies had also reported
beneficial effects regarding objective knowledge, risk
perception, and involvement in decision-making [40, 41,
58–60] and these could not be confirmed. The question
arises why these benefits could not be confirmed in our
study. Several explanations are possible, and might be
Table 4 Comparison of outcomes at a single time point (T2 or T3)
Measure (answer scale)1 Intervention group
N (%) or mean (SD)
Control group
N (%) or mean (SD)
p value
A dditional outcome measures: measurements at T2 n=68 n=40
Coping: Involvement
Perceived involvement: perception of being offered a choice (yes/no)2 45 (66%) 26 (67%) 0.959
Perceived involvement: perception whether patient’s opinion mattered (yes/no)2 51 (75%) 30 (77%) 0.823
Information-related measures
Undesired information (yes/no) 6 (10%) 7 (18%) 0.244
Balanced presentation of information (1-5) 2.7 (0.7) 2.4 (1.1) 0.201
Evaluation of information on treatment options: unpleasant (1-5) 2.1 (1.0) 2.2 (1.2) 0.679
Evaluation of information on treatment options: shocking (1-5) 2.3 (1.0) 2.3 (1.0) 0.958
Evaluation of information on treatment options: frightening (1-5) 2.4 (0.9) 2.2 (1.0) 0.347
Evaluation of information on severe adverse events: threatening (1-5) 2.5 (1.0) 2.7 (1.1) 0.358
Evaluation of information on tumour response: threatening (1-5) 2.7 (1.1) 2.7 (1.0) 0.786
Evaluation of information on survival: threatening (1-5) 3.0 (1.3) 2.6 (1.3) 0.112
Knowledge
Objective knowledge (1-5) 3.4 (1.3) 3.5 (1.3) 0.684
Subjective risk perception: severe adverse events (1-5) 2.2 (0.7) 2.0 (0.8) 0.242
Subjective risk perception: tumour response (1-7) 1.8 (1.1) 2.1 (1.1) 0.219
Subjective risk perception: pain (1-7) 3.0 (1.2) 3.2 (1.3) 0.461
Objective risk perception: diarrhoea (0-100%)3 30.9 (22.1) 34.9 (22.1) 0.366
Objective risk perception: tumour response (0-100%)3 30.0 (20.8) 32.5 (14.3) 0.463
Decision-related measures
Treatment choice: undecided (vs. decided) 1 (2%) 4 (10%) 0.068
Treatment choice: chemotherapy (vs. no chemotherapy) 63 (96%) 31 (84%) 0.067
Strength of treatment preference (1-5) 3.0 (1.0) 2.5 (1.2) 0.030
Additional outcome measures: measurements at T3 n=58 n=33
Coping: Involvement
Perceived involvement: perception of being offered a choice (yes/no)2 41 (71%) 20 (61%) 0.299
Perceived involvement: perception whether patient’s opinion mattered (yes/no)2 47 (81%) 25 (76%) 0.525
Decision-related measures
Treatment received: chemotherapy and BSC (vs. BSC alone) 50 (88%) 26 (84%) 0.746
Treatment attitudes toward the treatment received
Treatment satisfaction: received treatment (1-6) 4.6 (1.3) 4.6 (1.0) 0.794
Treatment satisfaction: physical consequences of treatment (1-6) 3.8 (1.5) 3.5 (1.3) 0.372
Treatment satisfaction: emotional consequences of treatment (1-6) 4.0 (1.4) 3.9 (1.3) 0.725
Abbreviation: BSC best supportive care
1More information on the scales can be found in Table 1
2Measured at T2 and T3
3Objective risk perception represents the absolute deviance between patient’s risk perception and actual risk as presented in the DA, based on literature reviews
[7, 8]
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related to: (1) the population of patients with advanced
cancer considering second-line palliative chemotherapy;
(2) the decision aids; or (3) the design of our trial.
First, in our interpretation, a similar relative absence
of effects was reported in the single randomised study
evaluating a DA on first-line palliative chemotherapy; a
positive effect was reported for objective knowledge, but
no positive effects were found for other commonly used
measures such as involvement [33]. Therefore, we might
contribute the absence of effects to the particular char-
acteristics of the population of vulnerable patients with
advanced cancer. Perhaps these patients did not perceive
the option to refrain from active treatment as a realistic
option. This has been suggested before [5, 61–64]. Also
data from our trial seem to suggest so, as patients valued
the appropriateness of best supportive care alone signifi-
cantly lower than best supportive care with chemother-
apy. Furthermore, a number of patients wrote down
open-ended comments on the patient questionnaires, in-
cluding 'I cannot value the appropriateness of BSC, be-
cause I have not discussed it or thought about it', 'I do
not have a choice', and 'The only thing that matters is
the effect of chemotherapy, adverse events do not matter
to me'. Previous research has shown that particularly for
second-line treatment, an important reason to opt for
active treatment is to promote hope [62–64].
Second, the DAs were offered by 20 different nurses
and after the consultation with the oncologist; timing
was tailored to local workflows and DAs may have been
offered relatively late in the decision-making process,
which may have reduced their value. It could also be hy-
pothesized that the added value of the DAs was reduced
because all patients in this study had previous experi-
ence with chemotherapy. Third, another explanation
could be related to a lack of statistical power of this
study since power was reduced by patient attrition at T2
and T3, however none of the differences between the
groups appears large enough to be clinically relevant.
One of the strengths of this study is that we performed
one of the few randomised evaluations of a DA for pal-
liative chemotherapy, and the first exploratory evaluation
for second-line treatment options. A further strength is
that we facilitated generalisability of the results by
recruiting patients from a large number of hospitals,
recruiting patients receiving first-line chemotherapy
while applying broad selection criteria, and achieving an
82% informed consent rate. Thorough attention was paid
to including evidence-based information in the DAs, by
performing systematic reviews which were subjected to
peer-review [7, 8].
Noteworthy limitations include multiple testing. A
total of 52 comparisons between the intervention and
control group were performed, of which two (4%)
reached statistical significance at the level p<0.05. These
two findings need to be interpreted with caution. An-
other limitation inherent to the nature of DAs is that
complete blinding was not possible. Nevertheless, oncol-
ogists were not aware of the allocation prior to random-
isation and our analysis showed no differences in clinical
and sociodemographic characteristics between rando-
mised and non-randomised patients.
Future studies might explore patients' perceptions of
palliative treatment choices, including ways to make pa-
tients aware that best supportive care without chemo-
therapy is a realistic treatment option. Studies might aim
to close the decision support loop by scheduling a con-
sultation with the oncologist after the DA is offered.
This allows patients time to think and have an informed
discussion with their oncologist. With regard to the
presentation of survival information, developers of fu-
ture DAs should consider offering patients survival in-
formation using typical, best-case and worst-case
scenarios instead of median survival [65].
Conclusions
Decision aids with detailed information on risks and
benefits of second-line palliative chemotherapy were
welcomed by the majority of patients with advanced
cancer and no adverse impact on patient well-being was
observed. These decision support tools can help to pro-
vide standardised information about potential risks and
benefits of available treatment options. While patients
reported some beneficial effects, other previously re-
ported benefits -including improvements in objective
knowledge, risk perception and involvement in decision-
making- were not confirmed for the decision aids in this
study. Results from this explorative trial have indicated
that even in a potentially vulnerable population of pa-
tients with advanced cancer beyond cure, decision aids
with detailed treatment-related information can be of-
fered, and this encouraging finding will hopefully stimu-
late further research in this field.
Additional files
Additional file 1: Changes from published study protocol. Overview
of changes in study design compared with the published protocol
(PDF 640 kb)
Additional file 2: Decision aid for second-line irinotecan. Example of
information provided in a decision aid. (PDF 89 kb)
Additional file 3: Inclusion and progression form. Copy of questionnaire
completed by clinicians at inclusion and progression. (PDF 79 kb)
Additional file 4: Questionnaire decision aid. Copy of nurse
questionnaire. (PDF 89 kb)
Additional file 5: Patient questionnaire 1. Copy of patient questionnaire
1 (T1, baseline). (PDF 236 kb)
Additional file 6: Patient questionnaire 2. Copy of patient questionnaire
2 (T2, one week follow-up). (PDF 402 kb)
Oostendorp et al. BMC Medical Informatics and Decision Making  (2017) 17:130 Page 11 of 14
Additional file 7: Patient questionnaire 3. Copy of patient questionnaire
3 (T3, eight week follow-up). (PDF 103 kb)
Abbreviations
ANCOVA: Analysis of covariance; BSC: Best supportive care; CI: Confidence
interval; DA: Decision aid; NTR: Netherlands Trial Registry; SD: Standard
deviation
Acknowledgements
The authors are grateful to all patients and health professionals for investing
their precious time in this study. Patients were accrued by clinicians at the
Medical Centre Alkmaar, the Jeroen Bosch Hospital in Den Bosch; the
Slingeland Hospital in Doetinchem; the Catharina Hospital in Eindhoven; the
Medical Spectrum Twente in Enschede, the St. Anna Hospital in Geldrop, the
University Medical Centre Groningen in Groningen; the St Jansdal Hospital in
Harderwijk; the Elkerliek Hospital in Helmond; the Medical Centre
Leeuwarden; the Radboud University Medical Centre in Nijmegen; the
Bernhoven Hospital in Oss; the St. Antonius Hospital in Nieuwegein and
Utrecht; the Bernhoven Hospital in Veghel; the Máxima Medical Centre in
Veldhoven; VieCuri Medical Centre in Venlo/Venray; and the Isala Clinics in
Zwolle. Eva Volmeijer, Mirte Sprengers, and Sanne Hobbelink are thanked for
their assistance with the data collection.
Funding
This work was supported by the Dutch Cancer Society [grant number KUN
2006-3465]. The funder had no role in the design of the study and collection,
analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
The dataset used during the current study is available from the
corresponding author on reasonable request.
Authors' contributions
PS and PO conceived of the study. LO, PS, PO, WG, RD contributed to the
design of the study. LO, PS, PO, AW, IS, TS contributed to data collection. LO,
PS, PO, WG, RD conducted data analysis and interpretation. LO and PS
drafted the first version of the manuscript with early involvement by PO and
WG. All authors critically revised the manuscript and approved the final
version of the manuscript.
Ethics approval and consent to participate
Ethical approval was obtained from the regional ethics review committee
(CMO Arnhem-Nijmegen) as well as the research ethics committees of all
participating hospitals. All patients included in the study provided written
informed consent. Obtaining informed consent from health professionals
was not required according to local regulations.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department for Health Evidence, Radboudumc, Nijmegen, the Netherlands.
2Department of Medical Oncology, Radboudumc, Nijmegen, the Netherlands.
3Department of Internal Medicine, VieCuri Medical Centre, Venlo, the
Netherlands. 4Department of Internal Medicine, Isala Clinics, Zwolle, the
Netherlands. 5Department of Medical Oncology, Jeroen Bosch Hospital, Den
Bosch, the Netherlands.
Received: 25 January 2017 Accepted: 21 August 2017
References
1. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: "when
is enough, enough?". JAMA. 2008;299(22):2667–78.
2. Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, Hayes
DM, Von Roenn JH, Schnipper LE. American Society of Clinical O. American
society of clinical oncology statement: toward individualized care for
patients with advanced cancer. J Clin Oncol. 2011;29(6):755–60.
3. Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ,
Garrido MM, Reid MC, Berlin DA, Adelson KB, et al. Chemotherapy Use,
Performance Status, and Quality of Life at the End of Life. JAMA
oncology. 2015;1(6):778–84.
4. Swetz KM, Smith TJ. Palliative chemotherapy: when is it worth it and when
is it not? Cancer J. 2010;16(5):467–72.
5. Koedoot CG, de Haan RJ, Stiggelbout AM, Stalmeier PF, de Graeff A, Bakker
PJ, de Haes JC. Palliative chemotherapy or best supportive care? A
prospective study explaining patients' treatment preference and choice. Br J
Cancer. 2003;89(12):2219–26.
6. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in
the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;
22(2):315–21.
7. Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der Graaf WT,
Ottevanger PB. Systematic review of benefits and risks of second-line
irinotecan monotherapy for advanced colorectal cancer. Anticancer Drugs.
2010;21(8):749–58.
8. Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB.
Efficacy and safety of palliative chemotherapy for patients with advanced
breast cancer pretreated with anthracyclines and taxanes: a systematic
review. Lancet Oncol. 2011;12(11):1053–61.
9. Porzsolt F, Tannock I. Goals of palliative cancer therapy. J Clin Oncol. 1993;
11(2):378–81.
10. Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations
between palliative chemotherapy and adult cancer patients' end of life care
and place of death: prospective cohort study. BMJ. 2014;348:g1219.
11. Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer
treatments: an overview of methods and applications in oncology. Ann
Oncol. 2012;23(5):1104–10.
12. Kadakia KC, Moynihan TJ, Smith TJ, Loprinzi CL. Palliative communications:
addressing chemotherapy in patients with advanced cancer. Ann Oncol.
2012;23(Suppl 3):29–32.
13. El-Jawahri A, Traeger L, Park ER, Greer JA, Pirl WF, Lennes IT, Jackson VA,
Gallagher ER, Temel JS. Associations among prognostic understanding,
quality of life, and mood in patients with advanced cancer. Cancer. 2014;
120(2):278–85.
14. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL,
Schrag D. Patients' expectations about effects of chemotherapy for
advanced cancer. N Engl J Med. 2012;367(17):1616–25.
15. Helft PR. Necessary collusion: prognostic communication with advanced
cancer patients. J Clin Oncol. 2005;23(13):3146–50.
16. The AM, Hak T, Koeter G, van Der Wal G. Collusion in doctor-patient
communication about imminent death: an ethnographic study. BMJ. 2000;
321(7273):1376–81.
17. Furber L, Cox K, Murphy R, Steward W. Investigating communication in
cancer consultations: what can be learned from doctor and patient
accounts of their experience? Eur J Cancer Care (Engl). 2013;22(5):653–62.
18. Hancock K, Clayton JM, Parker SM, Wal der S, Butow PN, Carrick S,
Currow D, Ghersi D, Glare P, Hagerty R, et al. Truth-telling in discussing
prognosis in advanced life-limiting illnesses: a systematic review. Palliat
Med. 2007;21(6):507–17.
19. Butow PN, Dowsett S, Hagerty R, Tattersall MH. Communicating prognosis
to patients with metastatic disease: what do they really want to know?
Support Care Cancer. 2002;10(2):161–8.
20. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M,
Llewellyn-Thomas H, Lyddiatt A, Legare F, Thomson R. Decision aids for
people facing health treatment or screening decisions. Cochrane Database
Syst Rev. 2011;10:CD001431.
21. de Haes H. Dilemmas in patient centeredness and shared decision making:
a case for vulnerability. Patient Educ Couns. 2006;62(3):291–8.
Oostendorp et al. BMC Medical Informatics and Decision Making  (2017) 17:130 Page 12 of 14
22. Keating NL, Beth Landrum M, Arora NK, Malin JL, Ganz PA, van Ryn M,
Weeks JC. Cancer patients' roles in treatment decisions: do characteristics of
the decision influence roles? J Clin Oncol. 2010;28(28):4364–70.
23. Cripe LD, Rawl SM, Schmidt KK, Tong Y, Monahan PO, Rand KL. Discussions
of life expectancy moderate relationships between prognosis and anxiety or
depression in men with advanced cancer. J Palliat Med. 2012;15(1):99–105.
24. Gattellari M, Voigt KJ, Butow PN, Tattersall MH. When the treatment goal is
not cure: are cancer patients equipped to make informed decisions? J Clin
Oncol. 2002;20(2):503–13.
25. Sepucha KR, Ozanne EM, Partridge AH, Moy B. Is there a role for decision
aids in advanced breast cancer? Med Decis Making. 2009;29(4):475–82.
26. Elit LM, Levine MN, Gafni A, Whelan TJ, Doig G, Streiner DL, Rosen B.
Patients' preferences for therapy in advanced epithelial ovarian cancer:
development, testing, and application of a bedside decision instrument.
Gynecol Oncol. 1996;62(3):329–35.
27. Anderson C, Carter J, Nattress K, Beale P, Philp S, Harrison J, Juraskova I. "The
booklet helped me not to panic": a pilot of a decision aid for asymptomatic
women with ovarian cancer and with rising CA-125 levels. Int J Gynecol
Cancer. 2011;21(4):737–43.
28. Fiset V, O'Connor AM, Evans W, Graham I, Degrasse C, Logan J.
Development and evaluation of a decision aid for patients with stage IV
non-small cell lung cancer. Health Expect. 2000;3(2):125–36.
29. Leighl NB, Shepherd FA, Zawisza D, Burkes RL, Feld R, Waldron J, Sun A,
Payne D, Bezjak A, Tattersall MH. Enhancing treatment decision-making:
pilot study of a treatment decision aid in stage IV non-small cell lung
cancer. Br J Cancer. 2008;98(11):1769–73.
30. Brundage MD, Feldman-Stewart D, Dixon P, Gregg R, Youssef Y, Davies
D, MacKillop WJ. A treatment trade-off based decision aid for patients
with locally advanced non-small cell lung cancer. Health Expect.
2000;3(1):55–68.
31. Smith TJ, Dow LA, Virago EA, Khatcheressian J, Matsuyama R, Lyckholm LJ. A
pilot trial of decision aids to give truthful prognostic and treatment
information to chemotherapy patients with advanced cancer. J Support
Oncol. 2011;9(2):79–86.
32. Chiew KS, Shepherd H, Vardy J, Tattersall MH, Butow PN, Leighl NB. Development
and evaluation of a decision aid for patients considering first-line chemotherapy
for metastatic breast cancer. Health Expect. 2008;11(1):35–45.
33. Leighl NB, Shepherd HL, Butow PN, Clarke SJ, McJannett M, Beale PJ,
Wilcken NR, Moore MJ, Chen EX, Goldstein D, et al. Supporting treatment
decision making in advanced cancer: a randomized trial of a decision aid
for patients with advanced colorectal cancer considering chemotherapy. J
Clin Oncol. 2011;29(15):2077–84.
34. Butler M, Ratner E, McCreedy E, Shippee N, Kane RL. Decision aids for
advance care planning: an overview of the state of the science. Ann Intern
Med. 2014;161(6):408–18.
35. Green MJ, Levi BH. Development of an interactive computer program for
advance care planning. Health Expect. 2009;12(1):60–9.
36. Vogel RI, Petzel SV, Cragg J, McClellan M, Chan D, Dickson E, Jacko JA,
Sainfort F, Geller MA. Development and pilot of an advance care planning
website for women with ovarian cancer: a randomized controlled trial.
Gynecol Oncol. 2013;131(2):430–6.
37. Volandes AE, Levin TT, Slovin S, Carvajal RD, O'Reilly EM, Keohan ML,
Theodoulou M, Dickler M, Gerecitano JF, Morris M, et al. Augmenting
advance care planning in poor prognosis cancer with a video decision aid:
a preintervention-postintervention study. Cancer. 2012;118(17):4331–8.
38. Oostendorp LJ, Ottevanger PB, van der Graaf WT, Stalmeier PF. Assessing
the information desire of patients with advanced cancer by providing
information with a decision aid, which is evaluated in a randomized trial: a
study protocol. BMC Med Inform Decis Mak. 2011;11:9.
39. Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Schoenaker IJ, de Graaf H,
van der Graaf WT, Stalmeier PF. Expected survival with and without second-
line palliative chemotherapy: who wants to know? Health Expect. 2015;
18(6):2903–14.
40. van Tol-Geerdink JJ, Leer JW, van Lin EN, Schimmel EC, Huizenga H, van
Daal WA, Stalmeier PF. Offering a treatment choice in the irradiation of
prostate cancer leads to better informed and more active patients, without
harm to well-being. Int J Radiat Oncol Biol Phys. 2008;70(2):442–8.
41. van Tol-Geerdink JJ, Leer JW, Weijerman PC, van Oort IM, Vergunst H, van
Lin EN, Alfred Witjes J, Stalmeier PF. Choice between prostatectomy and
radiotherapy when men are eligible for both: a randomized controlled trial
of usual care vs decision aid. BJU Int. 2013;111(4):564–73.
42. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R,
Barratt A, Barry M, Bernstein S, et al. Developing a quality criteria framework
for patient decision aids: online international Delphi consensus process.
BMJ. 2006;333(7565):417.
43. O'Connor AM, Stacey D, Entwistle V, Llewellyn-Thomas H, Rovner D,
Holmes-Rovner M, Tait V, Tetroe J, Fiset V, Barry M, et al. Decision aids for
people facing health treatment or screening decisions. Cochrane Database
Syst Rev. 2003;2:CD001431.
44. Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal important
difference of the hospital anxiety and depression scale in patients with
chronic obstructive pulmonary disease. Health Qual Life Outcomes.
2008;6:46.
45. Smid DE, Franssen FM, Houben-Wilke S, Vanfleteren LE, Janssen DJ,
Wouters EF, Spruit MA. Responsiveness and MCID Estimates for CAT,
CCQ, and HADS in Patients With COPD Undergoing Pulmonary
Rehabilitation: A Prospective Analysis. Journal of the American Medical
Directors Association. 2017;18(1):53–8.
46. Chan KS, Aronson Friedman L, Bienvenu OJ, Dinglas VD, Cuthbertson BH,
Porter R, Jones C, Hopkins RO, Needham DM. Distribution-based estimates
of minimal important difference for hospital anxiety and depression scale
and impact of event scale-revised in survivors of acute respiratory failure.
Gen Hosp Psychiatry. 2016;42:32–5.
47. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and
treatments. Lancet. 2005;365(9470):1591–5.
48. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67(6):361–70.
49. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley
A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, et al. The development of
the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in
palliative care. Eur J Cancer. 2006;42(1):55–64.
50. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side
effects of breast cancer screening. Health Psychol. 1991;10(4):259–67.
51. Watson M, Greer S, Young J, Inayat Q, Burgess C, Robertson B. Development
of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol
Med. 1988;18(1):203–9.
52. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in
treatment decision making? Arch Intern Med. 1996;156(13):1414–20.
53. Whelan TJ, Levine MN, Gafni A, Lukka H, Mohide EA, Patel M, Streiner DL.
Breast irradiation postlumpectomy: development and evaluation of a
decision instrument. J Clin Oncol. 1995;13(4):847–53.
54. Stalmeier PF, Roosmalen MS, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk
JC, Moog U, Hoogerbrugge N, van Daal WA. The decision evaluation scales.
Patient Educ Couns. 2005;57(3):286–93.
55. Armitage CJ, Conner M. Efficacy of the Theory of Planned Behaviour: a
meta-analytic review. Br J Soc Psychol. 2001;40(Pt 4):471–99.
56. Vodermaier A, Millman RD. Accuracy of the Hospital Anxiety and Depression
Scale as a screening tool in cancer patients: a systematic review and meta-
analysis. Support Care Cancer. 2011;19(12):1899–908.
57. Smith TJ, Dow LA, Virago E, Khatcheressian J, Lyckholm LJ, Matsuyama R.
Giving honest information to patients with advanced cancer maintains
hope. Oncology (Williston Park). 2010;24(6):521–5.
58. Neuman HB, Charlson ME, Temple LK. Is there a role for decision aids in
cancer-related decisions? Crit Rev Oncol Hematol. 2007;62(3):240–50.
59. Stacey D, Samant R, Bennett C. Decision making in oncology: a review of
patient decision aids to support patient participation. CA Cancer J Clin.
2008;58(5):293–304.
60. O'Brien MA, Whelan TJ, Villasis-Keever M, Gafni A, Charles C, Roberts R, Schiff
S, Cai W. Are cancer-related decision aids effective? A systematic review and
meta-analysis. J Clin Oncol. 2009;27(6):974–85.
61. Brom L, Pasman HR, Widdershoven GA, van der Vorst MJ, Reijneveld JC,
Postma TJ, Onwuteaka-Philipsen BD. Patients' preferences for participation
in treatment decision-making at the end of life: qualitative interviews with
advanced cancer patients. PLoS ONE. 2014;9(6):e100435.
62. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy
near the end of life? A review of the perspective of those facing death from
cancer. J Clin Oncol. 2006;24(21):3490–6.
63. Brom L, De Snoo-Trimp JC, Onwuteaka-Philipsen BD, Widdershoven GA,
Stiggelbout AM, Pasman HR. Challenges in shared decision making in
advanced cancer care: a qualitative longitudinal observational and interview
study. Health Expect. 2017;20(1):69–84.
Oostendorp et al. BMC Medical Informatics and Decision Making  (2017) 17:130 Page 13 of 14
64. Grunfeld EA, Maher EJ, Browne S, Ward P, Young T, Vivat B, Walker G, Wilson
C, Potts HW, Westcombe AM, et al. Advanced breast cancer patients'
perceptions of decision making for palliative chemotherapy. J Clin Oncol.
2006;24(7):1090–8.
65. Kiely BE, McCaughan G, Christodoulou S, Beale PJ, Grimison P, Trotman J,
Tattersall MH, Stockler MR. Using scenarios to explain life expectancy in
advanced cancer: attitudes of people with a cancer experience. Support
Care Cancer. 2013;21(2):369–76.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Oostendorp et al. BMC Medical Informatics and Decision Making  (2017) 17:130 Page 14 of 14
